Nýjar rannsóknir á Cleveland Clinic sýna í fyrsta skipti að ibrutinib (ibrutinib) sem samþykkt er af FDA vegna eitilæxlis og hvítblæðis getur einnig hjálpað til við að meðhöndla algengustu og banvænustu heilaæxli og gæti einhvern tíma verið notað hjá sjúklingum með glioblastoma og bætt lifunartíðni.
Samkvæmt skýrslu American Brain Tumor Association er lifunartíðni glioblastoma mjög lág og miðgildi lifunar sjúklinga sem fá hefðbundna meðferð er innan við 15 mánuðir. Glioblastoma er banvænasta frumheilaæxlið og er mjög ónæmt fyrir núverandi meðferðum. Brýnt er að veita þessum sjúklingum nýja meðferð eins fljótt og auðið er.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain æxli in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
